Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 27, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Repurchased: 1,940,000 Ordinary shares.
- Repurchase Price: 1,311.0466 pence per share.
- Treasury Shares Held: 412,273,158 shares (representing 7.34% of total voting rights).
- Shares in Issue: 5,611,814,566 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the increase in the company's Treasury shareholding following the open market purchase on September 27, 2007. The total number of shares held in Treasury now represents 7.34% of the total voting rights in the Company.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares in issue (5,611,814,566) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (412,273,158) and its percentage of voting rights (7.34%).
- Note that this filing does not contain quarterly or annual financial results; investors should refer to Form 20-F for comprehensive financial data.